Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …

Targeting highly proliferating cells is an important issue for many types of aggressive tumors.
Proliferating Cell Nuclear Antigen (PCNA) is an essential protein that participates in a variety …

Proliferating cell nuclear antigen (PCNA) is known as a molecular marker for proliferation
given its role in replication. Three identical molecules of PCNA form a molecular sliding …

Targeting transcription replication conflicts, a major source of endogenous DNA double-
stranded breaks and genomic instability could have important anticancer therapeutic …

The epidermal growth factor receptor (EGFR) has been one of the most targeted receptors in
the field of oncology. While anti-EGFR inhibitors have demonstrated clinical success in …

The epidermal growth factor receptor (EGFR) is one of the most well-studied signaling
pathways in cancer progression. As a result, numerous therapeutics including small …

Extensive research efforts have been made and are still ongoing in the search for an ideal
anti-cancer therapy. Almost all chemotherapeutics require a carrier or vehicle, a drug …

Abstract Treatment of triple-negative invasive breast cancers, defined by the absence of
estrogen and progesterone receptors and c-erbB2 expression, remains challenging …

The faithful DNA replication is a critical event for cell survival and inheritance. However,
exogenous or endogenous sources of damage challenge the accurate synthesis of DNA …

Triple-negative breast cancer (TNBC) has a high degree of malignancy, lack of effective
diagnosis and treatment, and poor prognosis. Bioinformatics methods are used to screen the …